{"nct_id":"NCT04796922","title":"To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)","status":"WITHDRAWN","status_verified_date":"2022-07","start_date":"2022-12-30","start_date_type":"ESTIMATED","primary_completion_date":"2028-12-20","primary_completion_date_type":"ESTIMATED","completion_date":"2032-08-25","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["INCY"]}